About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, July 8th, 2015

The QualityStocks
Daily Stock List


The MaryJane Group, Inc. (MJMJ)

Pennybuster, SmallCapFinancialWire, Penny Stock Bets, Wallstreetlivechat, and Greenbackers reported on The MaryJane Group, Inc. (MJMJ), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, The MaryJane Group, Inc. is the leading hospitality group in the marijuana industry. The Company has capitalized on the passing of Colorado Amendment 64, through establishing lodging accommodations dedicated to the growing canna-tourism industry. The MaryJane Group is based in Denver, Colorado.

The MaryJane Group owns and operates Bud+Breakfast™ locations. These are the Company’s cannabis-friendly lodges in the United States. It modeled its approach to hospitality after a traditional bed and breakfast. The Company provides clean rooms and comfortable share spaces, and also gourmet food prepared with fresh ingredients and first-class customer service.

The MaryJane Group has its “Bud+Breakfast™ at the Adagio” in Denver, Colorado. It is located in an elegant Victorian home in one of Denver’s most historic neighborhoods. The MaryJane Group announced this past March that it signed the contract to purchase The Adagio Bed and Breakfast in Denver. The total purchase price is $1,500,000.

The Bud+Breakfast™ at the Adagio is the first, premier cannabis-friendly lodge in Denver. It features six attractively decorated suites, each of them unique and private.

Furthermore, the Company has its “Bud+Breakfast™ at Mount Vista” in Silverthorne, Colorado. The Bud+Breakfast™ at Mount Vista is a blend of world-class skiing and legal cannabis. This property offers four private suites among two floors. Each floor features a kitchen, dining area, and lounge. The MaryJane Group presently provides cannabis-friendly lodging and events at these two Bud and Breakfast locations.

The MaryJane Group has recently partnered with Botanico, the premier recreational marijuana dispensary in Denver. Botanico offers the highest quality marijuana flower, concentrates, and THC-infused edibles in the city. Additionally, Botanico provides a very personal dispensary experience.

Last week, The MaryJane Group formally announced the continued growth of its popular Bud+Breakfast brand with the newly leased Hotel San Ayre in Colorado Springs. Hotel San Ayre will provide guests looking for a cannabis-themed vacation more opportunities for education and enjoyment. Bud+Breakfast San Ayre is a contemporary, boutique-inspired former motel property. It is situated in the heart of Colorado Springs.

Bud+Breakfast San Ayre includes a continental Wake+Bake Breakfast; and a 4:20 Happy Hour with complimentary beer, wine and hors d’oeuvres. It also includes a safe, social, cannabis-friendly environment.

The MaryJane Group, Inc. (MJMJ), closed Wednesday's trading session at $0.002, up 18.34%, on 139,074,810 volume with 601 trades. The average volume for the last 60 days is 52,779,810 and the stock's 52-week low/high is $0.0013/$0.77.

TransAKT Ltd. (TAKD)

We are highlighting TransAKT Ltd. (TAKD) today, here at the QualityStocks Daily Newsletter.

TransAKT Ltd. is a manufacturer of highly innovative agricultural equipment used to grow a large variety of vegetables and fruit using simulated sunlight from LED lamps in a proprietary hydroponic system. In addition, the Company is a worldwide distributor of LED lighting products focused on serving the fastest growing market of commercial, hospitality and outdoor lighting. TransAKT’s wholly-owned subsidiary is Vegfab Agriculture Technology Co., Ltd.  TransAKT’s shares trade on the OTC Markets’ OTCQB.

The Company’s commitment is to helping business owners in protecting the environment through superior energy efficiency - replacing current non-energy-efficient light sources with energy-efficient light sources.

Vegfab Agriculture Technology Co., Ltd. was established in 2010 by a team of ecologically minded semiconductor specialists knowledgeable about LED materials. Vegfab’s product line includes systems for commercial production and a home growing system, which enables families to grow safe and clean fruit and vegetables in their homes. Vegfab products are the subject of a number of patents. These include ones for vertically wall-mounted LED lights as well as ventilation systems for grow boxes.

TransAKT is centering on eliminating the use of chemical fertilizers and pesticides through the use of the latest hydroponic agricultural technology and pure nutrients. The nutrient solutions used in production with the Company’s hydroponic systems leave no heavy metal and chemical residues.

The Company's vegetable production factory in Yangmei City, Taiwan is the only mass production facility for vegetables in Taiwan. This facility uses pioneering technology to produce exceptional yields from a very small space. Production is extremely efficient through the use of simulated sunlight from LED lamps, up to 85 percent automated.

TransAKT earlier entered into a partnership with Taiwan Flora Seed International Co. Ltd. Taiwan Flora is an agricultural technology solution provider. It supplies finished products, training, and assistance to customers to setup greenhouse facilities and to successfully market their products.

TransAKT Ltd. (TAKD), closed Wednesday's trading session at $0.057, up 119.23%, on 1,094,666 volume with 26 trades. The average volume for the last 60 days is 22,859 and the stock's 52-week low/high is $0.02/$0.11.

CytoDyn, Inc. (CYDY)

PennyStockRumors and AllPennyStocks reported on CytoDyn, Inc. (CYDY), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

CytoDyn, Inc. is a biotechnology company listed on the OTCQB. It is focusing on developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). The Company has one of the leading mAbs under development for HIV infection - PRO 140.  CytoDyn is headquartered in Vancouver, Washington.

PRO 140 has finished Phase 2 clinical trials with demonstrated antiviral activity in man. PRO 140 is the Company’s novel self-injectable antibody for the treatment of HIV. PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells.

PRO 140 belongs to a new class of HIV/AIDS therapeutics - viral-entry inhibitors. The intention of these are to protect healthy cells from viral infection. PRO 140 blocks the HIV co-receptor CCR5. Clinical trial results so far indicate that it does not affect the normal function of the cell.

PRO 140 has been the subject of four Phase 1/1b and two Phase 2a clinical trials. Results from Phase 1/1b and Phase 2a human clinical trials have shown that PRO 140 can considerably reduce viral burden in people infected with HIV. CytoDyn’s intention is to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV.    

PRO 140 has also been designated a "fast track" product candidate by the Food and Drug Administration (FDA). The PRO 140 antibody appears to be a strong antiviral agent leading to potentially fewer side effects and less frequent dosing requirements in comparison to daily drug therapies presently in use.

CytoDyn has reached an agreement with the FDA on the Company's previously submitted Phase 3 protocol synopsis for PRO 140. It submitted the full Phase 3 protocol to the FDA on May 4, 2015. Its Phase 3 protocol provides for a 25-week study with 300 HIV patients that could begin as early as 30 days after submission.

CytoDyn’s recently completed Phase 2b treatment substitution trial demonstrated that 98 percent of all patients treated with PRO 140 successfully passed four weeks of monotherapy without virologic failure.

Last month, CytoDyn announced that it initiated its first Phase 3 study for PRO 140. Selection of clinical sites, IRB approvals, patients screening and other administrative matters are proceeding. The expectation is that they will be completed in time for the first patient to be dosed in Q3 of 2015.

Furthermore, in June, CytoDyn announced that recent Company research data has expanded the potential clinical indications for PRO 140, now in Phase 3 for the treatment of HIV, to include certain inflammatory diseases, autoimmunity, transplantation and cancer.

CytoDyn, Inc. (CYDY), closed Wednesday's trading session at $0.85, up 2.41%, on 92,817 volume with 26 trades. The average volume for the last 60 days is 78,318 and the stock's 52-week low/high is $0.54/$1.30.

Net Talk.com, Inc. (NTLK)

Epic Stock Picks, EpicVIP Group, TheMicrocapNews, Greenbackers, and Nebula Stocks reported earlier on Net Talk.com, Inc. (NTLK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Net Talk.com, Inc. (netTALK) is a leading ultra-low cost provider of home phone and smartphone communications. Its flagship product is the netTALK DUO. It enables anyone to Fire Your Phone Company® and never pay a monthly phone bill again. The netTALK DUO and the netTALK smartphone app are freeing consumers and small business owners from monthly phone bills and cellular talk minutes.

netTALK was established in 2008 by Anastasios “Takis” Kyriakides. His idea was to leverage the ongoing technology revolution to give consumers freedom of choice and to free them from outdated, expensive, legacy systems. NetTALK is based in Miami Gardens, Florida. The Company’s shares trade on the OTC Markets Group’s OTCQB.

netTALK and SHEnetics have a strategic partnership to jointly launch next generation intelligent phone services to netTALK's residential subscribers. The focus of these unique services are on voice powered personal assistant capabilities for enhanced voicemail, voice dialing, home control, calendaring, alerts, reminders, and web search.

SHEnetics is a pioneer in Artificial Intelligence (AI) based personal digital assistant technology. SHE Simulated Human Experience® is a technology platform for original equipment manufacturers (OEM's) and 3rd party developers to create custom Siri-like intelligent personal digital assistants for any connected device or service.

netTALK and Fantem recently announced a strategic partnership to provide a cost effective alternative to present home security options. Fantem is the creator of Oomi, an inventive smart home system. The solution, Oomi Personal Home Monitoring powered by netTALK, will provide users peace of mind that their property and loved ones are safe and secure, even when they are not home.

The service will be available as an add-on service to an Oomi smart home system. The Oomi Security Kit combines home security with smart home technology. This system uses Oomi's security features and takes advantage of netTALK's communication platform to allow users to proactively monitor their home and communicate with its occupants at a fraction of the cost of other home security solutions.

The Oomi Security Kit includes Oomi Cube, which is a sensor-packed brain for the entire system, and Oomi Touch, which is the main controller for the Oomi smart home system. The Kit also includes Oomi MultiSensor – a 6 in 1 sensor that includes motion detection, and Oomi Door & Window Sensors.

Net Talk.com, Inc. (NTLK), closed Wednesday's trading session at $0.0016, down 5.88%, on 2,018,927 volume with 12 trades. The average volume for the last 60 days is 6,766,621 and the stock's 52-week low/high is $0.0012/$0.20.

EV Charging USA, Inc. (EVUS)

Investor News Source, SmallCapAllStars, TryBestPennyStocks.biz, Wall Street Beauties, and WINNINGOTC reported on EV Charging USA, Inc. (EVUS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

EV Charging USA, Inc. specializes in consulting services to the EV industry with an emphasis on growth and profitability. The Company’s experienced Management team has the ability to evaluate and recommend the appropriate course of action for any system nationwide or worldwide. Founded in 2013, EV Charging USA lists on the OTC Markets Group’s OTCQB. The Company has its corporate head office in Chicago, Illinois.

EV Charging USA’s charging services and stations enable EV drivers to recharge their vehicles at commercial locations or in their own garages. The Company’s corporate mission is to become the greater Chicago market leader in the Electrical Vehicle Charging Station Industry. This is through owning and operating the largest system of Electric Car Chargers providing the highest level of service in the industry.

EV Charging USA will work closely with auto manufacturers and local dealerships. This is to expand the adaptations of electric car use.

Today, EV Charging USA announced its entrance into the EV Charging marketplace. After extensive research, it has chosen to launch an EV charging support related services division. The Company believes the potential in providing these services is not only national but international.

EV Charging USA reviewed a host of research and announcements by some of the leading automobile producers and researchers in the world. Navigant Research's new report "Electric Vehicle Charging Services" states that by 2023, when plug-in electric cars sold will reach 12 million, revenues from electric vehicle charging services will increase to $2.9 billion. It determined that this sector's growth potential is significant.

At first, EV Charging USA will focus on providing its consulting services to existing systems and system operators contemplating new markets. The services offered will include, but not be limited to consultation, identifying and evaluating new locations, and evaluating existing locations. Services offered will also include installation costs, proper equipment choice, installation vendor choices and an assortment of other related support services.

EV Charging USA, Inc. (EVUS), closed Wednesday's trading session at $0.18, down 5.26%, on 80,765 volume with 35 trades. The average volume for the last 60 days is 2,087 and the stock's 52-week low/high is $0.19/$0.245.


The QualityStocks
Company Corner


Fastfunds Financial Corp. (FFFC)

The QualityStocks Daily Newsletter would like to spotlight Fastfunds Financial Corp. (FFFC). Today, Fastfunds Financial Corp. closed trading at $0.0007, up 16.67%, on 7,229,125 volume with 28 trades. The stock’s average daily volume over the past 60 days is 9,854,958, and its 52-week low/high is $0.0005/$0.36.

Fastfunds Financial Corp. (FFFC) operates through two wholly owned subsidiaries, Cannabis Angel, Inc. and The 420 Development Corporation, to build a portfolio of revenue-generating companies that provide ancillary services to the burgeoning cannabis industry. The company also operates majority-owned subsidiary Financiera Moderna, Inc., which offers financial services to the underserved Hispanic community. FFFC's strategy to participate in the marijuana industry is through the development of four separate business verticals for the emerging U.S. cannabis industry.

Through its 49% stake in Cannabis Merchant Financial Solutions, Inc. (CMFS), FFFC entered the Financial Service business vertical. CMFS developed the Green Card and Tommy Chong Green Card, a reloadable stored value card with a rewards feature, and the Tommy Chong Frequent Buyers Card, which functions as a gift card or rewards card. FFFC is developing a national group of master resellers, distributors and sales representatives for these card products.

As the cannabis industry continues to develop, FFFC is partaking in Plant Botany, specifically the development of methods and technologies to significantly enhance plant growth and purity. Under an operating agreement with Sanidor Systems to create Pure Grow Systems, LLC, FFFC acquired a 49% interest in the subsidiary, which is dedicated to the healthy production and processing of raw materials used for medicinal or other health related purposes.

The cannabis industry is a cash-only business, which leaves companies vulnerable to criminal activities. FFFC plans to address this issue and enter the Security Services and Equipment sector through the acquisition of an existing, operational security company. FFFC owns a 70% stake in Ohio-based Brawnstone Security, Inc., a diversified security, training and investigations company. FFFC's research shows that operating margins for cannabis-related security services could exceed current billing levels by at least 100%.

FFFC's Cannabis Angel, Inc. ("CA") subsidiary will evaluate and provide corporate development services and early seed financing for worthwhile development-stage cannabis ventures. To date, CA has made investments in companies involved in the distribution of cannabis-related products and development of a social media website. It is important to note that all of FFFCs activities in the cannabis industry are ancillary, or pick and shovel, and are evaluated to insure compliance with all state and federal Laws. Disclaimer

Fastfunds Financial Corp. Company Blog

Fastfunds Financial Corp. News:

Fastfunds Financial Corporation Announces Major Milestone for Achieving National Distribution of Tommy Green Card

Fastfunds Financial Corporation Releases Mid-Year Letter to Update Stockholders

Fastfunds Financial Corporation Reports on Attendance at the Arizona Cannabis for Wellness Festival

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $13.40, up 5.10%, on 400 volume with 3 trades. The stock’s average daily volume over the past 60 days is 875, and its 52-week low/high is $3.16/$16.50.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Receives FDA and NIH Clearance to Initiate NIH-Funded Phase 2 Study of Orally Active AV-101 in Major Depressive Disorder

VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder

Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board

Galenfeha, Inc. (GLFH)

The QualityStocks Daily Newsletter would like to spotlight Galenfeha, Inc. (GLFH). Today, Galenfeha, Inc. closed trading at $0.41, up 2.55%, on 34,900 volume with 11 trades. The stock’s average daily volume over the past 60 days is 42,603, and its 52-week low/high is $0.1011/$4.00.

Galenfeha, Inc. (GLFH) is an engineering, product development, and manufacturing company that provides innovative solutions for oil and natural gas production, as well as stored energy products across a number of different industries. The company provides these products and services through its stored energy and oil & gas division.

Through its stored energy division, Galenfeha offers one of the most powerful, environmentally friendly battery systems in the market. The batteries have onboard computers, are inherently safe, internally temperature regulated, have optional GPS monitoring capabilities, offer significant weight reduction of up to 50%, and are engineered specifically for each type of application. Features include 100% “green” chemistry, RoHS compliancy, and active short circuit protection control.

Through its oil and gas division, the company offers chemical injection pumps that merge the perceived benefits of a hybrid, electric over pneumatic system. Galenfeha management believes the combination of the two parameter control systems represents a measurable shift in efficiency, reliability, cost management, and profitability to individual well locations as well as entire production fields. The combined technologies have demonstrated increased chemical injection accuracy, reducing chemical contamination in the production process while controlling cost and waste.

The company’s unwavering dedication is to continuously develop products that perform better than conventional solutions while also reducing environmental impact. Leveraging the management team’s wealth of resources and relationships, Galenfeha is well positioned for continued growth as the company aims to expand in both the stored energy and oil & gas industries. Disclaimer

Galenfeha, Inc. Company Blog

Galenfeha, Inc. News:

Galenfeha, Inc. Products Offered by Leading Power and Automation Company

Galenfeha Stored Energy Solutions Enters Aviation Industry

Galenfeha Broadens Oil and Gas Industry Penetration

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0033, even for the day. The stock’s average daily volume over the past 60 days is 114,765, and its 52-week low/high is $0.0013/$0.008.

Consorteum Holdings, Inc. (CSRH) has spent the last 3 years developing relationships and licensing agreements to take the center stage in the emerging market of mobile gaming. The company has the capability to deliver rich mobile content to end users who will use their smart phones in ways that could not even have been imagined five years ago.

Specializing in delivery of mobile content, mobile payment solutions and products through a mix of on-deck partnerships, license agreements, and joint venture revenue share arrangements, the company operates as a technology and services aggregator to meet the diverse needs of its client base. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

ThreeFiftyNine Inc., a wholly owned subsidiary, hired a software development team that had previously designed the world’s first regulatory compliant mobile platform for delivery of gaming content created by a third party. The platform, which has met the rigorous standards of the Nevada Gaming Board, the gold standard in regulatory gaming, represents the first generation software delivery platform for mobile devices. The development team spent the past 5 years and millions of dollars in non-recurring engineering costs to complete the development of the platform. At the heart is the capability to deliver any digital content across any cellular network to any mobile device. This key differentiator makes it possible for Consorteum to approach many different markets that are in the business of providing mobile connectivity and mobile content.

Consorteum’s mobile initiatives will benefit multiple business verticals. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Signs License Agreement With NYG Holdings

Consorteum Holdings Signs Mobile Application Development Contract With Bet Butler Limited

Consorteum Holdings Launches New Mobile Results App for Popular Keno Game

View Systems, Inc. (VSYM)

The QualityStocks Daily Newsletter would like to spotlight View Systems, Inc. (VSYM). Today, View Systems, Inc. closed trading at $0.0044, off by 2.22%, on 239,086 volume with 5 trades. The stock’s average daily volume over the past 60 days is 617,034, and its 52-week low/high is $0.0042/$0.029.

View Systems, Inc. (VSYM) is a leading security technology products company with “state-of-the-art” technological solutions for modern security problems. Targeting the challenging business opportunities in the opening decades of the 21st century and beyond, View Systems has solutions for law enforcement facilities such as correctional institutions as well as other government agencies, schools, courthouses, event and sports venues, the military and commercial businesses.

The senior management team is comprised of successful businessmen with decades of business and professional experience in the security industry. The approach used by View Systems utilizes the expertise of this team to provide innovative solutions to security problems with reliable “cutting edge” products in conjunction with client-oriented security consulting services.

The company’s flagship product, ViewScan, is an advanced walk-through Concealed Weapons Detection System (CWD) that greatly simplifies the process of discriminating suspicious items from harmless ones. The highly sensitive, completely passive sensor technology powering the system accurately detects the location and number of threat objects such as knives, guns and razor blades while ignoring personal artifacts like coins, keys and belt buckles. A portable version of this system has only a fifteen minute setup time using only a screwdriver and it easily fits inside a golf size case.

Experts say the security industry has been the fastest-growing sector of the global economy during the past decade. Today, it is conservatively estimated to be a $100 billion-a-year industry and growing. As the business environment continues to get more complex, especially in foreign markets, View Systems is strategically positioned to capitalize on unsurpassed opportunity. Disclaimer

View Systems, Inc. Company Blog

View Systems, Inc. News:

View Systems, Inc. Files for Patent, Begins Manufacturing of Enhanced ViewScan Product

View Systems Continues to Install Its Proprietary Scanning Systems Nationwide

View Systems, Inc. (VSYM) Announces Engagement of QualityStocks Investor Relations Services


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters








By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251